WICHITA, Kan., Oct. 1, 2014 /PRNewswire-USNewswire/ -- The Riordan Clinic is hosting its 4th Riordan IVC and Cancer Symposium on October 3rd and 4th, 2014 at the Hyatt Regency, Wichita KS. The symposium will explore the metabolic roots of cancer and the use of high dose intravenous vitamin C (IVC) as a therapy. Over 120 medical professionals and research scientists from around the world will attend the conference and take a collaborative look at the root causes of cancer and the use of IVC therapy as a safe and effective adjunct to conventional oncologic approaches.
How did this get started?
Thirty years ago, Dr. Hugh Riordan treated his first cancer patient with high doses of intravenous vitamin C. The patient was a 70 year-old gentleman with kidney cancer and metastasis to the liver and lungs. Dr. Riordan offered to treat this cancer patient "palliatively" with 30 grams of ascorbic acid (Vitamin C) intravenously twice a week. After 15 months of therapy, the cancer was gone. The patient died 12 years later…of congestive heart failure at age 84.
How is it relevant today?
Some 70,000 IVC infusions later, Dr. Riordan and his research team demonstrated that there is plausible scientific evidence to support the use of high dose ascorbate in the adjunctive care of cancer patients . Studies at the National Institutes of Health have since replicated and advanced these findings .
Interest continues to grow through practitioners from around the world who have adopted "The Riordan IVC Protocol" for the administration of high dose IVC for the treatment of cancer, viral infections and other health concerns in a non-toxic fashion.
Riordan Clinic hopes to kick off a bold new initiative to inform the public the safe and effective use of Intravenous Vitamin C. "Through scientific research, education and our extensive clinical experience with IVC, we believe the Riordan Clinic is well positioned to become the Vitamin C Capital of the World", says Brian Riordan, Riordan Clinic president and son of its founder, the late Dr. Hugh Riordan.
Under the direction and guidance of the clinic's chief medical officer, Ron Hunninghake, MD, this bold initiative will start with: the establishment of the Riordan IVC Academy to provide education and certification on the administration of the Riordan IVC Protocol; The 4th Riordan IVC and Cancer Symposium to address the "Metabolic Roots of Cancer"; and the founding of the Vitamin C Institute to unify the medical and scientific communities on vitamin c science and research.
More information on the Riordan IVC & Cancer Symposium and Riordan IVC Academy can be found online at: http://www.IVCandCancer.org
For more information about vitamin c research and the Riordan IVC Protocol, visit: http://www.riordanclinic.org/research/research-studies/vitaminc/protocol/
- Intravenous Ascorbate as a Tumor Cytotoxic Chemotherapeutic Agent. Riordan, N. H., Riordan, H. D., Meng, X., Li, Y., and Jackson, J. A. , Medical Hypotheses, 44(3), 207-13. 1995. http://www.ncbi.nlm.nih.gov/pubmed/7609676
- Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Chen Q1, Espey MG, Sun AY, Lee JH, Krishna MC, Shacter E, Choyke PL, Pooput C, Kirk KL, Buettner GR, Levine M., Proc Natl Acad Sci USA. 104(21):8749-54. 2007. http://www.ncbi.nlm.nih.gov/pubmed/17502596
About Riordan Clinic
Riordan Clinic is a 501(c)3 not-for profit organization focused on integrative medicine, clinical laboratory testing, health education and research. Since 1975, people worldwide have turned to Riordan Clinic for individualized, solutions-oriented, medical support. For more information about the Riordan Clinic, visit www.RiordanClinic.org
SOURCE Riordan Clinic